Luther R R, Klepper M J, Maurath C J, Glassman H N, Achari R, Laddu A R
Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois.
J Hum Hypertens. 1990 Apr;4(2):151-3.
The antihypertensive effects of the selective alpha 1-adrenoceptor antagonist, terazosin, in black patients with uncomplicated, mild to moderate essential hypertension were examined retrospectively in seven randomized, double-blind, placebo-controlled trials conducted in the United States. Following 4 to 13 weeks of treatment with terazosin (2-40 mg, once daily), supine and standing systolic and diastolic blood pressures were decreased significantly from baseline, and these decreases were significantly greater than those observed in the placebo group (P less than 0.05). Blood pressure changes in the black and white patient subgroups were comparable. Terazosin was generally well tolerated with a low incidence of serious side effects. We conclude that terazosin is a safe and effective antihypertensive agent in black patients with essential hypertension.
在美国进行的七项随机、双盲、安慰剂对照试验中，对选择性α1肾上腺素能受体拮抗剂特拉唑嗪在患有单纯性轻至中度原发性高血压的黑人患者中的降压作用进行了回顾性研究。在用特拉唑嗪（2 - 40毫克，每日一次）治疗4至13周后，仰卧位和站立位的收缩压和舒张压较基线水平显著降低，且这些降低幅度显著大于安慰剂组（P < 0.05）。黑人和白人患者亚组的血压变化具有可比性。特拉唑嗪总体耐受性良好，严重副作用发生率较低。我们得出结论，特拉唑嗪是治疗原发性高血压黑人患者的一种安全有效的抗高血压药物。
